Search company, investor...
Ensysce Biosciences company logo

Ensysce Biosciences

Founded Year



Reverse Merger | IPO

Total Raised


Market Cap


Stock Price


About Ensysce Biosciences

Ensysce Biosciences (NASDAQ: ENSC) (OTC: ENSCW) is focused on the use of fullerene carbon nanotubes for therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr. Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.

Headquarters Location

7946 Ivanhoe Avenue

La Jolla, California, 92037,

United States

(858) 263-4196

Compete with Ensysce Biosciences?

Ensure that your company and products are accurately represented on our platform.

Expert Collections containing Ensysce Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ensysce Biosciences is included in 3 Expert Collections, including Advanced Materials.


Advanced Materials

1,275 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Ensysce Biosciences Patents

Ensysce Biosciences has filed 6 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Prodrugs
patents chart

Application Date

Grant Date


Related Topics




Carbon nanotubes, Nanotechnology, Nanomaterials, Dosage forms, Drug delivery devices


Application Date


Grant Date



Related Topics

Carbon nanotubes, Nanotechnology, Nanomaterials, Dosage forms, Drug delivery devices



Latest Ensysce Biosciences News

10:56 ET Thinking about buying stock in Esports Entertainment, Faraday Future Intelligent Electric, Ensysce Biosciences, NVIDIA,...

Jan 25, 2023

News provided by Share this article Share this article NEW YORK, Jan. 25, 2023 /PRNewswire/ -- InvestorsObserver  issues critical PriceWatch Alerts for GMBL, FFIE, ENSC, NVDA, and MULN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment. InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options. SOURCE InvestorsObserver

Ensysce Biosciences Frequently Asked Questions (FAQ)

  • When was Ensysce Biosciences founded?

    Ensysce Biosciences was founded in 2003.

  • Where is Ensysce Biosciences's headquarters?

    Ensysce Biosciences's headquarters is located at 7946 Ivanhoe Avenue, La Jolla.

  • What is Ensysce Biosciences's latest funding round?

    Ensysce Biosciences's latest funding round is Reverse Merger.

  • How much did Ensysce Biosciences raise?

    Ensysce Biosciences raised a total of $14.19M.

  • Who are the investors of Ensysce Biosciences?

    Investors of Ensysce Biosciences include Leisure Acquisition, Global Emerging Markets, National Institute on Drug Abuse and Texas Emerging Technology Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.